pharma · Diabetes Mellitus · Hemophilia A
Takeda
NovaPharmaNews editorial coverage mentioning Takeda — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 1993
- Employees
- 1,617
- Programs
- 1179
- Drugs
- 359
- Patents
- 1436
News & analysis
NovaPharmaNews articles mentioning Takeda — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning Takeda — regulatory, clinical, and market analysis.
Takeda TYK2 drug tops Bristol Myers’ Sotyktu in psoriasis head-to-head test
Takeda’s TYK2 inhibitor zasocitinib outperformed Bristol Myers Squibb’s Sotyktu in a head-to-head plaque psoriasis trial. The result strengthens Takeda’s dermatology story and gives BD teams and investors a clearer read on the program’s competitive position.
Takeda and Novartis Layoffs: Implications for Pharma Industry
Takeda announces a reduction of 4,500 jobs while Novartis lays off biomedical research staff. This article explores the implications for the pharma sector.
Fierce Pharma Asia: Major Developments in Oncology and Workforce Changes
This article covers significant developments in the pharmaceutical sector, including BMS's $15B deal with Hengrui, Takeda's workforce reductions, and Daiichi's oncology initiatives.